For the quarter ending 2025-10-31, ODYY made $422,447 in revenue. -$483,447 in net income. Net profit margin of -114.44%.
| Income Statement | 2025-10-31 | 2025-07-31 | ||
|---|---|---|---|---|
| Research and development expense | - | 0 | ||
| General and administrative | 303,190 | 255,188.25 | ||
| Loss from operations | -303,190 | -255,188.25 | ||
| Gain on sale of product candidates and related assets | - | 0 | ||
| Impairment of investment in preferred stock of oragenics, inc | - | 0 | ||
| Loss from change in fair value of oragenics, inc. common stock | 0 | -114,854.25 | ||
| Interest expense | 95,336 | 63,129 | ||
| Financing costs | 507,368 | - | ||
| Change in fair value of derivative liability | 422,419 | - | ||
| Other income, net | 28 | -2,501.25 | ||
| Net loss and comprehensive loss | -483,447 | -435,672.75 | ||
| Deemed dividend | - | 0 | ||
| Net loss attributable to common stockholders | - | -435,672.75 | ||
| Basic net loss per share | 0 | -0.005 | ||
| Diluted net loss per share | 0 | -0.005 | ||
| Shares used for basic net loss per share | 106,036,632 | 26,177,440.75 | ||
| Shares used for diluted net loss per share | 106,036,632 | 26,177,440.75 | ||
Odyssey Health, Inc. (ODYY)
Odyssey Health, Inc. (ODYY)